



The National Office for Research Ethics Committees


Dr Emily Vereker, Head of Office




Strategic objective

Lead the transformation of the national research ethics system in Ireland to deliver a robust, efficient and transparent review framework that engenders the trust of key stakeholders, including the public

Irish health research regulatory landscape



National Office journey



March 2020 August 2020 Dec 2020 May 2021 Jan 2022 March 2022 May 2022



National Office Est.



EU MDR
May 2021

EU CTR
Jan 2022

EU IVDR
May 2022



S.I.260
May 2021

S.I.40/41
May 2022

S.I.257
May 2022

Committees at a glance

3 committees

68 members

COVID19
Sub-committee (x3)



National Irish COVID19
Biobank REC (x ~15)

Representing diverse
backgrounds, including:



ethics



Law



sciences /
health care
professionals



industry



social
sciences



Lay,
public,
patient



medical



public
health



statistics

From all
over Ireland



Core functions of the National Office



Cornerstone resources for trusted research ethics review guidance



WMA DECLARATION OF HELSINKI



Position of the European Network of Research Ethics Committees (EUREC) on the Responsibility of Research Ethics Committees during the COVID-19 Pandemic



Guideline for good clinical practice E6(R2) Step 5



Standards and Operational Guidance for Ethics Review of Health-Related Research with Human Participants



NUFFIELD COUNCIL ON BIOETHICS



Research in global health emergencies: ethical issues



World Health Organization

Ethical principles instilled by the NRECs



Value → enhancements of health or knowledge



Scientific validity → rigorous methodology



Justice → fair participant selection, inclusivity



Beneficence → maximising potential benefits, minimising risks



Informed consent → communication, privacy & protection




Respect, dignity, well-being → participant-centered approach, assisted decision-making



Independent review → no conflicts or affiliation

Opinions delivered to date

Year	New applications		Substantial amendments		Total	
	NREC-MD	NREC-CT	NREC-MD	NREC-CT	NREC-MD	NREC-CT
2021	10	49	7	216	17	265
2022	28	50	13	332	41	382
Total	38	99	20	548	58	647



80 meetings



705
opinions

Time to decision: approx. 39 days

Substantial Amendments - bootcamp


	# Amendments considered	Decisions made		
		Request for further information	Favourable	Favourable with conditions
Week 1	20	1	13	6
Week 2	20	4	14	2
Week 3	20	5	9	6
Week 4	20	9	2	9
Week 5	20	8	9	3
Week 6	15	3	4	8
Week 7	12	0	7	5
Week 8	7	3	4	
Total	134	33	62	39

- Submissions greatly exceeded volume forecast –
- Backlog in early 2022
- 8 week Bootcamp
 - 14 members from CT-A/B came forward to help tackle the task
- Current process
 - 2 Subcommittees /month
 - Monitoring
 - Current average time from validation to decision: 25 days

CTD → CTR Transition 2023

NREC	SUBMISSION CUT OFF DATES 2022/2023	MEETING DATE
NREC CT B	10 November 2022	23 November 2022
NREC CT A	24 November 2022	7 December 2022
NREC CT B	*Break*	*Break*
NREC-CT B	15 December 2022	11 January 2023
NREC-CT A	11 January 2023	25 January 2023
NREC-CT B	25 January 2023 (last date for submission of valid new applications under the CTD*)	8 February 2023
NREC-CT A	8 February 2023 (all submissions must be through the CTIS system under the CTR)	22 February 2023
NREC-CT B	1 March 2023	15 March 2023
NREC-CT A	15 March 2023	29 March 2023

Changes for the NREC-CTs



- Part I and Part II do not need to be submitted together:
 - NREC-CT may be reviewing Part I and Part II separately – potentially 2 years apart
 - No requirement for an applicant to submit a Part II
- NREC-CT will only have one opportunity to request changes or further information under an 'RFI' for both Part I and Part II
- Applicant can appeal an NREC-CT decision

6 new applications

1 substantial amendment

5 transition trials

Changes for the NREC-MD

Clinical investigations of medical devices (MDR)

- Systematic investigation
- involving one or more human participants,
- undertaken to assess the safety or performance of a medical device.



Performance studies of in vitro diagnostic medical devices (IVDR):

- Study undertaken to establish or confirm the analytical or clinical performance of an in vitro device



- Remit defined by MDR & IVDR
- Oversight of studies under MDD

- Mandate for single national opinion
- Independent review by HPRA

Forward looking 2023



- Enable the NREC members to deliver trusted national opinions under new legislative frameworks → operational effectiveness, preparedness,



- Strengthen our engagement & collaborate with local RECs for alignment & harmonisation → REC community of practice
- Build further on collaborations with our stakeholders → HPRA, DOH, HSE, HRB



- Instil international best practice - engagement with international experts, bioethics councils, EU counterparts, EMA working groups



- Support research initiatives of national importance, supporting excellence in innovative health and social service → COVID19




- Advocate for patient, public and carer entered approach



- Operate with agility & pragmatism

National Office Team





THANK YOU

Visit us and subscribe for updates at www.nrecoffice.ie

Find us on Twitter and LinkedIn

Enabling a trusted national ethics opinion

